Francesco Franchi

Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease

Dominick J. Angiolillo, Joseph A. Jakubowski, José Luis Ferreiro et al. · Journal of the American College of Cardiology · 2014 · 179 citations

Metabolic Syndrome, Platelet Aggregation Inhibitors, Thrombosis +14

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Francesco Franchi, Fabiana Rollini, Andrea Rivas et al. · Circulation · 2019 · 148 citations · Full text

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials

Mattía Galli, Stefano Benenati, Francesco Franchi et al. · European Heart Journal · 2021 · 146 citations · Full text

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial

Robert F. Storey, Dominick J. Angiolillo, Marc P. Bonaca et al. · Journal of the American College of Cardiology · 2016 · 124 citations · Full text

Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotype‐Guided Antiplatelet Therapy

Philip E. Empey, James M. Stevenson, Sony Tuteja et al. · Clinical Pharmacology & Therapeutics · 2017 · 124 citations · Full text

Patient Selection, Pharmacotherapy, Thrombosis +17